Login to Your Account


Transcelerate Biopharma Inc., a nonprofit established by 10 of the industry's largest pharmas in 2012, is launching Biocelerate, a new subsidiary that aims to improve efficiencies in preclinical research, first by working to illuminate the relationship between patient response and preclinical toxicology findings.

Yumanity Therapeutics pulled down a $45 million series A led by Fidelity Management & Research Co. – "the investment group, not the venture group," Tony Coles, chairman and CEO, clarified – in a vote of institutional confidence that "almost never happens" in an early round, he said.

Executives at Oasmia Pharmaceutical AB came to the J.P. Morgan Healthcare Conference (JPM) recently confident they had every chance of perking up investor interest in their story.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: